NAI

Natural Alternatives International Scheduled to Reopen U.S. Manufacturing Facility in California to Support Increased Production Needs

Retrieved on: 
Tuesday, April 2, 2024
Natural Alternatives International, NAI, Foot

NAI temporarily closed the facility in October 2023 due to a significant reduction in customer orders.

Key Points: 
  • NAI temporarily closed the facility in October 2023 due to a significant reduction in customer orders.
  • NAI purchased the Carlsbad facility in August 2021 and spent 21 months retrofitting the space with a heavy focus on efficient high-volume powder production and gusseted bag packaging.
  • “Restarting our facility is a direct result of our growing capacity needs,” shared Mark LeDoux, Chairman and Chief Executive Officer of NAI.
  • NAI’s expanding manufacturing capabilities is advantageous for our customers and for our local workforce.”

New Amsterdam Invest N.V. will publish audited annual report 2023 on 29 April 2024 D.V.

Retrieved on: 
Monday, April 8, 2024
Operation, One half, Annual report, Euronext Amsterdam, NAI, AGM, Acquisition, Renting

AMSTERDAM, April 8, 2024 /PRNewswire/ -- New Amsterdam Invest N.V. (the "Company", or "New Amsterdam Invest", or "NAI"), a commercial real estate company listed on Euronext Amsterdam, announces it rescheduled publication of its audited annual report 2023 to 29 April 2024 and AGM to 21 June 2024.

Key Points: 
  • AMSTERDAM, April 8, 2024 /PRNewswire/ -- New Amsterdam Invest N.V. (the "Company", or "New Amsterdam Invest", or "NAI"), a commercial real estate company listed on Euronext Amsterdam, announces it rescheduled publication of its audited annual report 2023 to 29 April 2024 and AGM to 21 June 2024.
  • Until 2 June 2023 the Company operated as a SPAC and only per that date acquired its operating companies.
  • The Board of NAI is strongly committed to deliver the market and its investors a comprehensive set of audited accounts and hence rescheduled publication of the 2023 annual report, originally due today, to 29 April 2024.
  • The AGM agenda will be published on 29 April and the new AGM date has been set at 21 June 2024.

Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

Retrieved on: 
Monday, March 25, 2024
Letter, Emergent, Risk, Patient, CGMP, Ethics, Classification, News, EBS, Life, NAI, Emergent BioSolutions, VAI, FDA, Food, Management

GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI status classification for the company's Baltimore Bayview manufacturing facility.

Key Points: 
  • GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed “No Action Indicated” or NAI status classification for the company's Baltimore Bayview manufacturing facility.
  • Based on this outcome, the Baltimore Bayview facility is considered to be in an acceptable state of compliance with regard to current good manufacturing practices (cGMP).
  • “We will continue to put quality and compliance first in our manufacturing operations to ensure we’re delivering high quality products to our customers and patients.”
    The result of obtaining NAI status in Bayview is a continuation of Emergent’s strong commitment to quality and compliance.
  • In 2023, Emergent manufacturing facilities were successfully inspected by five regulatory agencies across the globe and five other inspectional bodies for 18 inspections, including three by the FDA that resulted in NAI or VAI status.

First Phosphate Corp. Receives Mining Research and Innovation Grant from Quebec Ministry of Natural Resources

Retrieved on: 
Monday, March 4, 2024
Mining, OTC, Phosphate, PPA, Natural Resources, LFP, Forestry, PDAC, NAI, Saguenay–Lac-Saint-Jean, Research

Saguenay, Quebec--(Newsfile Corp. - March 4, 2024) - First Phosphate Corp. (CSE: PHOS) (OTC: FRSPF) (FSE: KD0) ("First Phosphate" or the "Company") is pleased to have recently received a mining research and innovation grant from the Quebec Ministry of Natural Resources and Forestry ("MRNF").

Key Points: 
  • Saguenay, Quebec--(Newsfile Corp. - March 4, 2024) - First Phosphate Corp. (CSE: PHOS) (OTC: FRSPF) (FSE: KD0) ("First Phosphate" or the "Company") is pleased to have recently received a mining research and innovation grant from the Quebec Ministry of Natural Resources and Forestry ("MRNF").
  • The grant provides financial support to the Company in the way of $315,236 to continue mineralogical study on its apatite, ilmenite and magnetite concentrates.
  • The project also includes the processing of the Company's mine tailings for re-use in the cement construction industry.
  • "We are grateful to the Quebec Ministry of Natural Resources and Forests for this funding as we continue to build strong relationships with Quebec-based government bodies and institutions," said Company CEO, John Passalacqua.

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG

Retrieved on: 
Monday, February 5, 2024
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Gemcitabine, Quality of life, Rated R, Docetaxel, NAI, NMIBC, Patient, Safety, CIS, UCLA, DSS, Pros, PRO, Incidence, Progression-free survival, Cancer, Diagnosis, FDA, SOC, Medicine, Cystectomy, Global health, Experiment (probability theory), DFS, Pembrolizumab, Carcinoma in situ, PDUFA, Associate, Bladder cancer, BCG, BLA, Bacillus

Overall, participants who achieved a complete response with the novel combination therapy reported better physical function by month six of the study than those who did not achieve a complete response.

Key Points: 
  • Overall, participants who achieved a complete response with the novel combination therapy reported better physical function by month six of the study than those who did not achieve a complete response.
  • “Many current therapies for bladder cancer slow disease progression but can cause debilitating side effects,” said Principal Investigator Karim Chamie, M.D., Associate Professor of Urology at UCLA.
  • Bladder cancer is the 10th most-commonly diagnosed cancer, with approximately 80% of newly diagnosed cases being NMIBC.
  • Safety and efficacy have not been established by any Health Authority or Agency, including the FDA.

IonQ Co-Founder Dr. Jungsang Kim Elected Fellow of the National Academy of Inventors

Retrieved on: 
Wednesday, January 17, 2024
Defense, Military, Automotive Manufacturing, Logistics, Supply Chain Management, Air, Manufacturing, Transport, Other Technology, Other Energy, Other Science, Utilities, Software, Research, Networks, Other Defense, Internet, Contracts, Alternative Energy, Hardware, Energy, Automotive, Technology, Semiconductor, Science, Nanotechnology, General Automotive, Government Technology, NAI, University, Invention, Multimedia, Partnership, Barium, National academy, Government, Patent, Television

IonQ (NYSE: IONQ), a leader in the quantum computing industry, today announced co-founder Dr. Jungsang Kim has been named a 2023 fellow of the National Academy of Inventors (NAI), the highest professional distinction awarded solely to inventors.

Key Points: 
  • IonQ (NYSE: IONQ), a leader in the quantum computing industry, today announced co-founder Dr. Jungsang Kim has been named a 2023 fellow of the National Academy of Inventors (NAI), the highest professional distinction awarded solely to inventors.
  • Kim joins an esteemed cohort of NAI fellows who will be honored during the NAI’s 13th annual conference on June 16-18 in Raleigh, NC.
  • Throughout his career, Kim has accumulated 35 patents, 19 of which are licensed to IonQ.
  • To learn more about how you can get started on an IonQ system today, please visit https://ionq.com/get-ready

Swoop Launches Predictive AI Targeting, the Next Generation of Healthcare Marketing

Retrieved on: 
Thursday, January 4, 2024
Pharmaceutical, Health, Marketing, Artificial Intelligence, Advertising, Communications, Health Technology, Technology, DTC, HCP, Diagnosis, Patient, NAI, Algorithm, Network, Physician, Medical device

"Swoop's first-to-market predictive AI targeting allows brands to further refine their healthcare marketing, helping advertisers fill critical information gaps in the patient and provider journey,” said Swoop President, Scott Rines.

Key Points: 
  • "Swoop's first-to-market predictive AI targeting allows brands to further refine their healthcare marketing, helping advertisers fill critical information gaps in the patient and provider journey,” said Swoop President, Scott Rines.
  • “The healthcare journey, from initial consultation to diagnosis, treatment and continuing care, is multifaceted, intricate and unique for every patient,” added Rines.
  • Swoop is HIPAA-certified, a member of the Network Advertising Initiative (NAI) and all its technology is built on a patented privacy-by-design data infrastructure.
  • For more information about Swoop's Predictive AI Segments, please visit www.swoop.com .

IAB Privacy Unveils Accountability Program as Part of its Multi-State Privacy Agreement for Signatories to Earn Certification

Retrieved on: 
Tuesday, November 14, 2023
General counsel, Privacy, IAB, NAI, MSPA, Signature, Certification, Audit

NEW YORK, Nov. 14, 2023 /PRNewswire/ -- Continuing its efforts to promote consumer privacy and comply with new state privacy laws, IAB Privacy (IAB) has established a voluntary Accountability Program as part of its Multi-State Privacy Agreement (MSPA) compliance framework.

Key Points: 
  • NEW YORK, Nov. 14, 2023 /PRNewswire/ -- Continuing its efforts to promote consumer privacy and comply with new state privacy laws, IAB Privacy (IAB) has established a voluntary Accountability Program as part of its Multi-State Privacy Agreement (MSPA) compliance framework.
  • Through the Accountability Program, MSPA Signatories have an opportunity to earn an 'MSPA Certified' seal after demonstrating how they comply with the requirements of the MSPA.
  • To receive this certification, MSPA Signatories who choose to participate must submit to an assessment, which will be conducted by an Authorized Assessor designated by IAB.
  • The MSPA Accountability Program is currently available only to ad tech companies who have signed the MSPA (known as "Downstream Participants" in the MSPA).

DeepIntent Joins the Network Advertising Initiative (NAI)

Retrieved on: 
Tuesday, November 14, 2023
Research, Organization, Interactivity, International Association, Privacy, GPP, IAB, NAI, DAA, Interactive Advertising Bureau, Data collection, Health, Digital, IAPP, AdChoices, Health care, TAG, Network, Network Advertising Initiative

NEW YORK, Nov. 14, 2023 /PRNewswire/ -- Healthcare advertising technology leader DeepIntent announced its membership in the Network Advertising Initiative (NAI), the leading self-regulatory association dedicated to responsible data collection and its use in digital advertising in the United States. As part of the NAI, DeepIntent furthers its commitment to building technology that empowers pharmaceutical advertisers to reach their most relevant audiences in a privacy-safe way.

Key Points: 
  • NEW YORK, Nov. 14, 2023 /PRNewswire/ -- Healthcare advertising technology leader DeepIntent announced its membership in the Network Advertising Initiative (NAI), the leading self-regulatory association dedicated to responsible data collection and its use in digital advertising in the United States.
  • As part of the NAI, DeepIntent furthers its commitment to building technology that empowers pharmaceutical advertisers to reach their most relevant audiences in a privacy-safe way.
  • Given the current privacy landscape, DeepIntent believes supporting a unified industry standard is more important than ever.
  • "These new NAI guidelines are well-aligned with DeepIntent's vision of privacy-safe targeting," said Yashina Burns, Vice President of Legal and Privacy at DeepIntent.

Designing Chips with CHIPS: West Coast Pre-Silicon Summit to Convene Industry Leaders in San Diego

Retrieved on: 
Tuesday, October 31, 2023
APS, 3D, Irwin, Software, CHIPS and Science Act, DRAM, Policy, IBM Fellow, HBT, Ammunition Design Group, Government, DTCO, UC Berkeley College of Engineering, All-star, University of California, Berkeley, Commerce, Silicon–germanium, Indiana University–Purdue University Indianapolis, NDIA, European Chips Act, College, NAI, EDA, Purdue University, IEEE, Synopsys, UCLA, Mass communication specialist, Engineering education, IP, IBM, National Advanced Youth Leadership Experience, Distinguishing, Performance, Internet, SAN, Video game, Woman, Engineering, CHIPS, Qualcomm, Salicide

SAN DIEGO, Oct. 31, 2023 /PRNewswire/ -- On 3 November, 2023, the "Designing Chips with CHIPS: West Coast Pre-Silicon Summit" will gather influential minds in the chip design and packaging industry, along with key government policy makers, for a one-day, in-person summit at Irwin M Jacobs Qualcomm Hall in Qualcomm Headquarters, San Diego, California.

Key Points: 
  • SAN DIEGO, Oct. 31, 2023 /PRNewswire/ -- On 3 November, 2023, the "Designing Chips with CHIPS: West Coast Pre-Silicon Summit" will gather influential minds in the chip design and packaging industry, along with key government policy makers, for a one-day, in-person summit at Irwin M Jacobs Qualcomm Hall in Qualcomm Headquarters, San Diego, California.
  • The summit aims to provide industry leaders, particularly those involved in the computer chip manufacturing sector, with essential insights into how the CHIPS Act will impact their businesses.
  • We are thrilled to host this summit in Region 6 and our greater San Diego area."
  • To learn more about the "Designing Chips with CHIPS: West Coast Pre-Silicon Summit" and to register for this exclusive event, please visit https://chipdesign.ieeeusa.org/ .